Adding apalutamide (Erleada) to androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer reduced the risk of developing metastases and castration-resistant disease, ...

Metformin failed to prevent metabolic syndrome in men on hormonal therapy for prostate cancer but did improve risk factors ...

Source: Getty Images High-dose radiotherapy “needs the addition of short-term ADT to improve outcomes in intermediate- and high-risk localized prostate cancer,” according to Nicolas Demogeot, MD. The ...

Adding a longer course of androgen deprivation therapy to postoperative radiotherapy may prolong metastasis-free survival in patients with prostate cancer. Adding a longer course of androgen ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ORLANDO -- ...

The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 ...

BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that it has submitted a Marketing Authorisation Application to the European Medicines Agency ...

Androgen-deprivation therapy (ADT) has, for more than 70 years, been the mainstay of treatment for patients with metastatic prostate cancer. Now, results of a phase III clinical trial reveal that ...

The number of diagnosed prevalent drug-treated mHSPC cases in the 8MM will rise from 196,867 in 2025 to 244,101 by 2033.